In 3 patients with proved pheochromocytoma, circulating catecholamine concentrations, vanillylmandelic acid and total free catecholamine urinary excretion, dopamine-beta-hydroxylase activities in plasma were measured the day before surgery, during the removal of the tumour and postoperatively. Following the removal of the pheochromocytoma, all these parameters declined with a different rate, possibly related to the half-life proper to each molecule. The results showing a decrease in plasma D beta H activities after the removal of the tumors are in good accordance with most authors. The mechanism and the meaning of catecholamines release from non-innervated tumor-cells remain to be elucidated. By considering these three cases, it does not seem that the evolution of D beta H activity after removal of the tumor is dependent upon the fact that the pheochromocytoma releases preferentially either epinephrine or nephinephrine.
Download full-text PDF |
Source |
---|
Xenobiotica
October 2024
Department of Research and Development, BIAL - Portela & Ca. S.A., São Mamede do Coronado, Portugal.
The metabolism and disposition of zamicastat, a reversible dopamine β-hydroxylase (DβH) inhibitor, developed for treatment of Pulmonary Arterial Hypertension (PAH), were investigated in rats after oral and intravenous administration of [C]-zamicastat.Zamicastat was rapidly absorbed and widely distributed to peripheral tissues, with total radioactivity almost completely recovered 168 h post-dose. Its main route of excretion was via faeces, whilst urine and expired air had minor roles.
View Article and Find Full Text PDFBr J Clin Pharmacol
November 2024
Department of Biomedicine, Unit of Pharmacology & Therapeutics, Faculty of Medicine, University of Porto, Portugal.
Aims: Dopamine beta-hydroxylase (DβH) inhibitors, like zamicastat, hold promise for treating pulmonary arterial hypertension. This study aimed to validate the mechanism of action of zamicastat by studying its effect on the overdrive of the sympathetic nervous system (SNS).
Methods: A single-centre, prospective, double-blind, randomized, placebo-controlled, crossover study evaluated the effect of 400 mg zamicastat in 22 healthy male subjects.
J Clin Pharmacol
November 2024
Department of Biomedicine, Unit of Pharmacology & Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.
This study intended to evaluate the interactions between zamicastat and epoprostenol in healthy human subjects. This was a single-center, open-label, two-period study. In period 1, epoprostenol 8 ng/kg/min was administered alone.
View Article and Find Full Text PDFCell Immunol
July 2024
Asieris Pharmaceuticals Co., Ltd, Palo Alto, CA, USA. Electronic address:
Background: Inflammatory bowel disease (IBD) is a chronic and relapsing disease characterized by immune-mediated dysfunction of intestinal homeostasis. Alteration of the enteric nervous system and the subsequent neuro-immune interaction are thought to contribute to the initiation and progression of IBD. However, the role of dopamine beta-hydroxylase (DBH), an enzyme converting dopamine into norepinephrine, in modulating intestinal inflammation is not well defined.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!